Skip to main content

Preclinical Research of Mesenchymal Stem Cell-Based Therapy for Ocular Diseases

  • Living reference work entry
  • First Online:
Handbook of Stem Cell Therapy

Abstract

Mesenchymal stem cells (MSC) are specific cell types that enable tissue renewal within the body and are activated during the regeneration processes in response to injury. These cells are present in all human and animal tissues. In medical and biological research, MSCs are isolated and purified from the donor organism and cultured in vitro before use in the treatment of a variety of diseases and conditions associated with tissue damage and cell loss, including ocular lesions. This approach is called cell-based therapy or regenerative medicine. Despite the many existing therapeutic strategies in the area of cell therapy in relation to curing ocular diseases in recent years, advances and new regenerative therapy methods have also been developed and consolidated, giving us a new perspective. Therefore, it is necessary to implement standardization and comparison of cell therapy results. Experimentation using animal models has played a central role in biomedical research. The safety and efficacy of new drugs are usually tested in animal models of human diseases prior to entering human clinical trials. Nevertheless, the pathophysiological mechanisms of eye diseases are complex and multifactorial; hence it is crucial that experimental animal models with clinical relevance provide adequate information and sufficiently replicate the eye diseases being assessed and demonstrate the effects of MSC therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Abbreviations

ADMSC:

Adipose-derived mesenchymal stem cells

AMD:

Age-related macular degeneration

BDNF:

Brain-derived neurotrophic factor

BMSC:

Bone marrow stromal cells

CNV:

Choroidal neovascularization

DR:

Diabetic retinopathy

ES:

Embryonic stem cells

GCL:

Ganglion cell layer

GFP:

Green fluorescent protein

PVPC:

Multipotent perivascular progenitor cells derived from human

hESC:

Embryonic stem cells

hRPC:

Human retinal progenitor cells

LEC:

Lens epithelial cells

LHON:

Leberโ€™s hereditary optic neuropathy

MSC:

Mesenchymal stem cells

NF1:

Neurofibromatosis type 1

POAG:

Primary open-angle glaucoma

RCS:

Retinal dystrophy of Royal College of Surgeons rats

RGC:

Retinal ganglion cells

RP:

Retinitis pigmentosa

RPE:

Retinal pigment epithelial cells

SC:

Stem cells

UMSC:

Umbilical cord mesenchymal stem cells

References

Download references

Acknowledgments

This work was funded by the subsidy allocated to KFU for the state assignment 0671-2020-0058 in the sphere of scientific activities. This work is part of the Kazan Federal University Strategic Academic Leadership Program.

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

ยฉ 2022 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Zakirova, E., Aimaletdinov, A.M., Malanyeva, A.G., Rutland, ะก.S., Rizvanov, A.A. (2022). Preclinical Research of Mesenchymal Stem Cell-Based Therapy for Ocular Diseases. In: Haider, K.H. (eds) Handbook of Stem Cell Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-16-6016-0_12-1

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-6016-0_12-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-6016-0

  • Online ISBN: 978-981-16-6016-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics